Quantcast

Latest Thalidomide Stories

2008-06-17 03:00:38

Celgene Corporation David Gryska, 908-673-9059 Sr. Vice President and Chief Financial Officer or Brian P.

2008-06-16 12:00:11

Vion Pharmaceuticals has reported positive data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine in elderly patients with acute myelogenous leukemia and high-risk myelodysplastic syndromes.

2008-06-14 12:00:24

Celgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced a significant survival gain regardless of the number of prior therapies they had received.

2008-06-14 06:00:27

Celgene International Sarl (Nasdaq:CELG) today announced that according to data from a pooled study presented at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark, multiple myeloma patients taking REVLIMID(R) (lenalidomide) plus dexamethasone significantly increased their survival rates.

2006-06-05 09:46:06

ATLANTA (Reuters) - Celgene Inc.'s cancer drug Revlimid improves the rate of survival in previously treated patients with the blood cancer multiple myeloma by at least a year compared with those taking standard treatment, according to data released on Monday.

2006-06-04 09:36:46

ATLANTA (Reuters) - Celgene Inc. said on Sunday its cancer drug Thalomid improved survival by a significant amount in elderly patients with multiple myeloma, a form of blood cancer.

2006-04-13 10:44:37

NEW YORK (Reuters Health) - Treatment with thalidomide or its analog lenalidomide prolongs life in mice with amyotrophic lateral sclerosis (ALS), scientists report. Lead investigator Dr.

2006-01-09 09:03:39

SAN FRANCISCO (Reuters) - Celgene Corp. said on Monday that a pivotal-stage trial of its Thalomid drug was stopped early after the medicine was shown to dramatically limit the progress of the blood cancer multiple myeloma.

2006-01-09 07:44:20

SAN FRANCISCO (Reuters) - Celgene Corp. said on Monday that a pivotal-stage trial of its Thalomid drug was stopped early after the medicine was shown to dramatically limit the progress of the blood cancer multiple myeloma.

2005-09-28 00:01:10

NEW YORK (Reuters) - A clinical trial of Celgene Corp.'s experimental cancer drug, Revlimid, has been suspended because of concerns about blood clots, the Wall Street Journal reported on Wednesday.


Word of the Day
marcescent
  • Withering but not falling off, as a blossom that persists on a twig after flowering.
The word 'marcescent' comes from a Latin word meaning 'to wither'.
Related